Sygnature Discovery Collaborates with DaltonTx to Advance AI-enabled Drug Discovery
Sygnature Discovery has partnered with AI firm DaltonTx to sharpen its drug discovery pipeline, bringing faster medicinal chemistry decisions and tighter data privacy to its CRO offering.
DaltonTx's Dalton platform unifies data, models, and experimental results into a single learning system supporting both biologics and small-molecule programs. It joins Sygnature's existing computational and medicinal chemistry stack — including SygDesign, BullFrog AI, and Iktos — with the goal of faster, better-informed decisions across discovery programs.
Sygnature is already stress-testing the partnership through a retrospective analysis of a legacy oncology program built around a small molecule candidate now in Phase I, assessing whether Dalton could have cut the path to candidate selection by reducing synthesis burden and sharpening decision-making.
A key differentiator is data privacy: customer data and AI models are siloed on a per-program basis, ensuring no project's information trains models used elsewhere.
"AI in drug discovery continues to evolve rapidly, but we believe the future lies in combining the power of machine learning with the expertise and intuition of experienced scientists," said Simon Hirst, CEO of Sygnature Discovery. "By helping scientists make better-informed decisions earlier in the discovery process, we can reduce the number of compounds synthesized and tested, shorten DMTA cycles and accelerate progression toward candidate selection."
"The next phase of AI in drug discovery is about impact," said Garry Pairaudeau, CEO and Co-Founder of DaltonTx. "We believe the organizations that capture the most value from AI will be those that connect their teams, tools and data into systems that improve real-world discovery decisions. Dalton unifies data, models, and experimental results to capture what worked, what failed and why, with full context so judgment compounds over time."
